Search results
X4 Pharma Highlights New Data Supporting Mavorixafor's Broad Potential In Chronic Neutropenia
Benzinga via Yahoo Finance· 2 years agoX4 Pharmaceuticals Inc (NASDAQ: XFOR) announced new data from its Phase 1b trial evaluating the...
Ono Pharmaceutical acquires cancer-focused biopharma Deciphera for $2.4bn
Pharmaceutical Technology via Yahoo Finance· 1 month agoDeciphera Pharmaceuticals is set to be acquired in a $2.4bn buyout, as the biopharma announced that...
Why Shares of Savara Soared This Week
Motley Fool· 1 year agoWhat happened Shares of Savara (NASDAQ: SVRA), a clinical-stage biopharmaceutical company that specializes in rare respiratory diseases, were up 31.6%...
Kiniksa Pharmaceuticals (KNSA) Up 14.7% YTD: Here's How
Zacks via Yahoo Finance· 7 months agoKiniksa Pharmaceuticals, Ltd. KNSA has been performing well in the last six months, thanks to...
What Causes Sweet Syndrome?
Verywell Health via Yahoo News· 11 months agoSweet syndrome (acute febrile neutrophilic dermatosis) is a rare disorder that causes a sudden onset of a tender skin rash along with fever. A rise in...
Zacks Industry Outlook Highlights Gilead Sciences, GSK, Immunocore and Syndax Pharmaceuticals
Zacks via Yahoo Finance· 1 year agoFor Immediate Release Chicago, IL – December 28, 2022 – Today, Zacks Equity Research discusses...
Humanigen (HGEN) Surges on Lenzilumab Study Data for Leukemia
Zacks via Yahoo Finance· 1 year agoHumanigen's (HGEN) shares surge after presenting promising early results of its Precision Approach...
Syndax's (SNDX) Leukemia Drug Gets FDA Breakthrough Therapy Tag
Zacks via Yahoo Finance· 2 years agoThe FDA bestows a Breakthrough Therapy designation to Syndax's (SNDX) revumenib for treating...
The 3 Most Undervalued Biotech Stocks to Buy Now: June 2023
InvestorPlace via Yahoo Finance· 11 months agoNow is a great time to accumulate top undervalued biotech stocks. For one, the sector is...
Syndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDA
Zacks via Yahoo Finance· 2 months agoSyndax Pharmaceuticals (SNDX) groundbreaking menin inhibitor, revumenib, receives FDA priority...
